Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

3',4'-Dimethoxyflavone and valproic acid promotes the proliferation of human hematopoietic stem cells.

Kaur K, Mirlashari MR, Kvalheim G, Kjeldsen-Kragh J.

Stem Cell Res Ther. 2013 May 24;4(3):60. doi: 10.1186/scrt208.

2.

Valproic acid affects the engraftment of TPO-expanded cord blood cells in NOD/SCID mice.

Vulcano F, Milazzo L, Ciccarelli C, Barca A, Agostini F, Altieri I, Macioce G, Di Virgilio A, Screnci M, De Felice L, Giampaolo A, Hassan HJ.

Exp Cell Res. 2012 Feb 15;318(4):400-7. doi: 10.1016/j.yexcr.2011.11.012. Epub 2011 Dec 6.

PMID:
22166516
3.

Valproic acid enhances the engraftability of human umbilical cord blood hematopoietic stem cells expanded under serum-free conditions.

Seet LF, Teng E, Lai YS, Laning J, Kraus M, Wnendt S, Merchav S, Chan SL.

Eur J Haematol. 2009 Feb;82(2):124-32. doi: 10.1111/j.1600-0609.2008.01169.x. Epub 2008 Nov 10.

PMID:
19067743
4.

Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells.

De Felice L, Tatarelli C, Mascolo MG, Gregorj C, Agostini F, Fiorini R, Gelmetti V, Pascale S, Padula F, Petrucci MT, Arcese W, Nervi C.

Cancer Res. 2005 Feb 15;65(4):1505-13.

5.

Differential effects of epigenetic modifiers on the expansion and maintenance of human cord blood stem/progenitor cells.

Mahmud N, Petro B, Baluchamy S, Li X, Taioli S, Lavelle D, Quigley JG, Suphangul M, Araki H.

Biol Blood Marrow Transplant. 2014 Apr;20(4):480-9. doi: 10.1016/j.bbmt.2013.12.562. Epub 2013 Dec 26.

6.

Valproic acid triggers erythro/megakaryocyte lineage decision through induction of GFI1B and MLLT3 expression.

Zini R, Norfo R, Ferrari F, Bianchi E, Salati S, Pennucci V, Sacchi G, Carboni C, Ceccherelli GB, Tagliafico E, Ferrari S, Manfredini R; AGIMM Investigators.

Exp Hematol. 2012 Dec;40(12):1043-1054.e6. doi: 10.1016/j.exphem.2012.08.003. Epub 2012 Aug 10.

PMID:
22885124
7.

Sca-1 is an early-response target of histone deacetylase inhibitors and marks hematopoietic cells with enhanced function.

Walasek MA, Bystrykh LV, Olthof S, de Haan G, van Os R.

Exp Hematol. 2013 Jan;41(1):113-23.e2. doi: 10.1016/j.exphem.2012.09.004. Epub 2012 Sep 16.

PMID:
22989761
8.

Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal.

Young JC, Wu S, Hansteen G, Du C, Sambucetti L, Remiszewski S, O'Farrell AM, Hill B, Lavau C, Murray LJ.

Cytotherapy. 2004;6(4):328-36.

PMID:
16146885
9.

Ex vivo expansion of human hematopoietic stem cells by garcinol, a potent inhibitor of histone acetyltransferase.

Nishino T, Wang C, Mochizuki-Kashio M, Osawa M, Nakauchi H, Iwama A.

PLoS One. 2011;6(9):e24298. doi: 10.1371/journal.pone.0024298. Epub 2011 Sep 12.

10.

Use of IL3 and chromatin-modifying reagents valproic acid and 5-aza-2'-deoxycytidine to affect mobilized peripheral blood CD34+ cell fate decisions.

Liu J, Samuel K, Turner ML, Gallagher RC.

Vox Sang. 2014 Jul;107(1):83-9. doi: 10.1111/vox.12124. Epub 2014 Jan 27.

PMID:
24460712
11.

Dynamic cell-cell interactions between cord blood haematopoietic progenitors and the cellular niche are essential for the expansion of CD34+, CD34+CD38- and early lymphoid CD7+ cells.

da Silva CL, Gonçalves R, dos Santos F, Andrade PZ, Almeida-Porada G, Cabral JM.

J Tissue Eng Regen Med. 2010 Feb;4(2):149-58. doi: 10.1002/term.226.

PMID:
19937912
12.

A potential activity of valproic acid in the stimulation of interleukin-3-mediated megakaryopoiesis and erythropoiesis.

Liu B, Ohishi K, Yamamura K, Suzuki K, Monma F, Ino K, Nishii K, Masuya M, Sekine T, Heike Y, Takaue Y, Katayama N.

Exp Hematol. 2010 Aug;38(8):685-95. doi: 10.1016/j.exphem.2010.03.019. Epub 2010 Apr 8. Erratum in: Exp Hematol. 2010 Sep;38(9):845. Nishii, Kazuhiro [added].

PMID:
20381581
13.

Role of epigenetic reprogramming in hematopoietic stem cell function.

Iancu-Rubin C, Hoffman R.

Curr Opin Hematol. 2015 Jul;22(4):279-85. doi: 10.1097/MOH.0000000000000143. Review.

PMID:
26049747
15.

Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia.

Bug G, Schwarz K, Schoch C, Kampfmann M, Henschler R, Hoelzer D, Ottmann OG, Ruthardt M.

Haematologica. 2007 Apr;92(4):542-5.

16.

Epigenetic and molecular signatures of cord blood CD34(+) cells treated with histone deacetylase inhibitors.

Gajzer D, Ross J, Winder L, Navada S, Zhang W, Silverman L, Chaurasia P.

Vox Sang. 2016 Jan;110(1):79-89. doi: 10.1111/vox.12303. Epub 2015 Jun 17.

PMID:
26084882
17.

Cytokine combinations on the potential for ex vivo expansion of murine hematopoietic stem cells.

Lui WC, Chan YF, Chan LC, Ng RK.

Cytokine. 2014 Aug;68(2):127-32. doi: 10.1016/j.cyto.2014.04.008. Epub 2014 May 11.

PMID:
24825677
18.

Histone deacetylase 3 modulates the expansion of human hematopoietic stem cells.

Elizalde C, Fernández-Rueda J, Salcedo JM, Dorronsoro A, Ferrin I, Jakobsson E, Trigueros C.

Stem Cells Dev. 2012 Sep 20;21(14):2581-91. doi: 10.1089/scd.2011.0698. Epub 2012 May 8.

PMID:
22455388
19.

Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells.

Bug G, Gül H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X, Beissert T, Boehrer S, Hoelzer D, Ottmann OG, Ruthardt M.

Cancer Res. 2005 Apr 1;65(7):2537-41.

20.

The combination of valproic acid and lithium delays hematopoietic stem/progenitor cell differentiation.

Walasek MA, Bystrykh L, van den Boom V, Olthof S, Ausema A, Ritsema M, Huls G, de Haan G, van Os R.

Blood. 2012 Mar 29;119(13):3050-9. doi: 10.1182/blood-2011-08-375386. Epub 2012 Feb 10.

Supplemental Content

Support Center